New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study
Hao-Yu Wang,Ke-Fei Dou,Changdong Guan,Lihua Xie,Yunfei Huang,Rui Zhang,Weixian Yang,Yongjian Wu,Yuejin Yang,Shubin Qiao,Runlin Gao,Bo Xu,Hao-Yu WangKe-Fei DouChangdong GuanLihua XieYunfei HuangRui ZhangWeixian YangYongjian WuYuejin YangShubin QiaoRunlin GaoBo XuDepartment of Cardiology,Cardiometabolic Medicine Center,Coronary Heart Disease Center,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China. (H.-Y.W.,K.-F.D.,R.Z.,W.Y.,Y.W.,Y.Y.,S.Q.,R.G.)Catheterization Laboratories,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China. (C.G.,L.X.,Y.H.,B.X.)State Key Laboratory of Cardiovascular Disease,Beijing,China (H.-Y.W.,K.-F.D.,R.Z.,Y.W.,Y.Y.).National Clinical Research Center for Cardiovascular Diseases,Beijing,China (K.-F.D.,W.Y.,Y.W.,Y.Y.,S.Q.,R.G.,B.X.).
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.121.011536
2022-05-20
Abstract:The appropriate duration of dual antiplatelet therapy (DAPT) and risk-benefit ratio for long-term DAPT in patients with left main (LM) disease undergoing percutaneous coronary intervention remains uncertain. Four thousand five hundred sixty-one consecutive patients with stenting of LM disease at a single center from January 2004 to December 2016 were enrolled. Decision to discontinue or remain on DAPT after 12 months was left to an individualized decision-making based on treating physicians by weighing the patient's risks of ischemia versus bleeding and considering patient preference. The primary outcome was a composite of death, myocardial infarction, stent thrombosis, or stroke at 3 years. Key safety outcome was 3-year rate of Bleeding Academic Research Consortium 2, 3, or 5 bleeding. Of 3865 patients free of ischemic and bleeding events at 12 months, 1727 (44.7%) remained on DAPT (mostly clopidogrel based [97.7%]) beyond 12 months after LM percutaneous coronary intervention. DAPT>12-month versus ≤12-month DAPT was associated with a significant reduced risk of 3-year primary outcome (2.6% versus 4.6%; adjusted hazard ratio: 0.59 [95% CI, 0.41–0.84]). The same trend was found for other ischemic end points: death (0.9% versus 3.0%; P log-rank <0.001), cardiovascular death (0.5% versus 1.7%; P log-rank =0.001), myocardial infarction (0.8% versus 1.9%; P log-rank =0.005), and stent thrombosis (0.4% versus 1.1%; P log-rank =0.017). The key safety end point was not significantly different between 2 regimens (1.8% versus 1.6%; adjusted hazard ratio: 1.07 [95% CI, 0.65–1.74]). The effect of DAPT>12 month on primary and key safety outcomes was consistent across clinical presentations, high bleeding risk, P2Y 12 inhibitor, and LM bifurcation percutaneous coronary intervention approach. In a large cohort of patients free from clinical events during the first year after LM percutaneous coronary intervention and at low apparent future bleeding risk, an individualized patient-tailored approach to longer duration (>12 month) of DAPT with aspirin plus a P2Y 12 inhibitor (mostly clopidogrel) improved both composite and individual efficacy outcomes by reducing ischemic risk, without a concomitant increase in clinically relevant bleeding. Download figure Download PowerPoint
cardiac & cardiovascular systems